This Chemotherapy-Induced Myelosuppression Treatment market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The chemotherapy-induced myelosuppression treatment market size has grown strongly in recent years. It will grow from $7.97 billion in 2024 to $8.37 billion in 2025 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to the increasing need for early diagnosis, increasing incidence of leukemia, and growing emphasis on research and development.
The chemotherapy-induced myelosuppression treatment market size is expected to see steady growth in the next few years. It will grow to $10.04 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to the increasing number of cancer patients, Increased awareness among patients, and increasing adoption of new therapies. Major trends in the forecast period include increased cost-effective treatment, the adoption of AI algorithm solutions, notable technological advancements, and launches of new products and services.
The increasing prevalence of cancer is anticipated to drive the growth of the chemotherapy-induced myelosuppression treatment market in the future. Cancer is characterized by the uncontrolled growth and spread of abnormal cells, which often invade surrounding tissues and organs, disrupting their normal functions and potentially threatening the individual's overall health and well-being. The rising incidence of cancer can be attributed to exposure to pollution, radiation, certain chemicals, and carcinogens. Chemotherapy-induced myelosuppression treatment is crucial in cancer care for managing the hematological side effects caused by chemotherapy, a standard treatment for various cancer types. For example, in May 2024, the American Society of Clinical Oncology, a US-based professional organization, reported an estimated 20 million new cancer cases in 2022, with projections reaching 35 million new cases globally by 2050. Thus, the increasing prevalence of cancer is fueling the chemotherapy-induced myelosuppression treatment market.
The growth of the chemotherapy-induced myelosuppression treatment market is expected to be driven by the rising healthcare expenditures. Healthcare expenditures represent the total resources spent by individuals, organizations, and governments on healthcare services, goods, and infrastructure, such as hospital care, physician services, nursing care, and other health-related activities. The increase in healthcare spending is driven by factors like an aging population, advancements in medical technology, a growing prevalence of chronic diseases, and rising healthcare service and prescription drug costs. Higher healthcare expenditures result in better access to advanced treatments for chemotherapy-induced myelosuppression, including new medications, medical technologies, and supportive care interventions, leading to improved patient outcomes. For example, in May 2024, the Office for National Statistics, a UK government department, reported that total healthcare spending in the UK rose by 5.6% in nominal terms from 2022 to 2023, a notable increase compared to the 0.9% growth in 2022. In 2023, government funding contributed $309 billion (£239 billion), or 81.9% of the nation's healthcare expenditure, making it the main source of healthcare financing. Consequently, the rise in healthcare spending is fueling the expansion of the chemotherapy-induced myelosuppression treatment market.
In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately $43 billion. With this acquisition, Pfizer aims to expand its portfolio in oncology and biopharmaceuticals by leveraging Seagen's expertise in antibody-drug conjugates and targeted cancer therapies. This move is intended to strengthen Pfizer's position in the oncology market and advance patient treatment options. Seagen Inc. is a US-based company that develops innovative monoclonal antibody-based therapies for chemotherapy-induced myelosuppression.
Major companies operating in the chemotherapy-induced myelosuppression treatment market are Merck & Co. Inc., Bayer AG, Sanofi SA, Abbott Laboratories, Novartis AG, Glaxo Smith Kline plc, Amgen Inc., Viatris Inc., Biogen SA, Bausch Health Companies Inc., Cipla Inc., Hikma Pharmaceuticals PLC,Lupin Ltd, Seagen Inc, Mission Pharmacal Company, G1 Therapeutics Inc., Spectrum Pharmaceuticals Inc., Partner Therapeutics Inc., Myelo Therapeutics GmbH, Evive Biotech Inc.
North America was the largest region in the chemotherapy-induced myelosuppression treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced myelosuppression treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemotherapy-induced myelosuppression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Chemotherapy-induced myelosuppression treatment involves therapeutic interventions designed to manage and alleviate the suppression of bone marrow activity caused by chemotherapy drugs. The objective of treating chemotherapy-induced myelosuppression is to alleviate symptoms, prevent complications such as infections or bleeding disorders, and support patients in continuing their chemotherapy treatment.
The primary indications for chemotherapy-induced myelosuppression treatment are anemia, neutropenia, and thrombocytopenia. Anemia in this context refers to a condition where the body lacks sufficient healthy red blood cells, leading to fatigue, weakness, and shortness of breath. The various classes of drugs used include growth factors, erythropoietin-stimulating agents, thrombopoietic agents, iron supplements, and others. The market for chemotherapy-induced myelosuppression treatment includes oral and injectable routes of administration, distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
The chemotherapy-induced myelosuppression treatment market research report is one of a series of new reports that provides chemotherapy-induced myelosuppression treatment market statistics, including chemotherapy-induced myelosuppression treatment industry global market size, regional shares, competitors with a chemotherapy-induced myelosuppression treatment market share, detailed chemotherapy-induced myelosuppression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy-induced myelosuppression treatment industry. This chemotherapy-induced myelosuppression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chemotherapy-induced myelosuppression treatment market includes revenues earned by entities by providing services such as red blood cell transfusions, platelet transfusions, antibiotic therapy, and supportive care and related erythropoiesis-stimulating agents, antibiotics, colony-stimulating factors (CSFs), diagnostic kits and hydration solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The chemotherapy-induced myelosuppression treatment market size has grown strongly in recent years. It will grow from $7.97 billion in 2024 to $8.37 billion in 2025 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to the increasing need for early diagnosis, increasing incidence of leukemia, and growing emphasis on research and development.
The chemotherapy-induced myelosuppression treatment market size is expected to see steady growth in the next few years. It will grow to $10.04 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to the increasing number of cancer patients, Increased awareness among patients, and increasing adoption of new therapies. Major trends in the forecast period include increased cost-effective treatment, the adoption of AI algorithm solutions, notable technological advancements, and launches of new products and services.
The increasing prevalence of cancer is anticipated to drive the growth of the chemotherapy-induced myelosuppression treatment market in the future. Cancer is characterized by the uncontrolled growth and spread of abnormal cells, which often invade surrounding tissues and organs, disrupting their normal functions and potentially threatening the individual's overall health and well-being. The rising incidence of cancer can be attributed to exposure to pollution, radiation, certain chemicals, and carcinogens. Chemotherapy-induced myelosuppression treatment is crucial in cancer care for managing the hematological side effects caused by chemotherapy, a standard treatment for various cancer types. For example, in May 2024, the American Society of Clinical Oncology, a US-based professional organization, reported an estimated 20 million new cancer cases in 2022, with projections reaching 35 million new cases globally by 2050. Thus, the increasing prevalence of cancer is fueling the chemotherapy-induced myelosuppression treatment market.
The growth of the chemotherapy-induced myelosuppression treatment market is expected to be driven by the rising healthcare expenditures. Healthcare expenditures represent the total resources spent by individuals, organizations, and governments on healthcare services, goods, and infrastructure, such as hospital care, physician services, nursing care, and other health-related activities. The increase in healthcare spending is driven by factors like an aging population, advancements in medical technology, a growing prevalence of chronic diseases, and rising healthcare service and prescription drug costs. Higher healthcare expenditures result in better access to advanced treatments for chemotherapy-induced myelosuppression, including new medications, medical technologies, and supportive care interventions, leading to improved patient outcomes. For example, in May 2024, the Office for National Statistics, a UK government department, reported that total healthcare spending in the UK rose by 5.6% in nominal terms from 2022 to 2023, a notable increase compared to the 0.9% growth in 2022. In 2023, government funding contributed $309 billion (£239 billion), or 81.9% of the nation's healthcare expenditure, making it the main source of healthcare financing. Consequently, the rise in healthcare spending is fueling the expansion of the chemotherapy-induced myelosuppression treatment market.
In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately $43 billion. With this acquisition, Pfizer aims to expand its portfolio in oncology and biopharmaceuticals by leveraging Seagen's expertise in antibody-drug conjugates and targeted cancer therapies. This move is intended to strengthen Pfizer's position in the oncology market and advance patient treatment options. Seagen Inc. is a US-based company that develops innovative monoclonal antibody-based therapies for chemotherapy-induced myelosuppression.
Major companies operating in the chemotherapy-induced myelosuppression treatment market are Merck & Co. Inc., Bayer AG, Sanofi SA, Abbott Laboratories, Novartis AG, Glaxo Smith Kline plc, Amgen Inc., Viatris Inc., Biogen SA, Bausch Health Companies Inc., Cipla Inc., Hikma Pharmaceuticals PLC,Lupin Ltd, Seagen Inc, Mission Pharmacal Company, G1 Therapeutics Inc., Spectrum Pharmaceuticals Inc., Partner Therapeutics Inc., Myelo Therapeutics GmbH, Evive Biotech Inc.
North America was the largest region in the chemotherapy-induced myelosuppression treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced myelosuppression treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemotherapy-induced myelosuppression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Chemotherapy-induced myelosuppression treatment involves therapeutic interventions designed to manage and alleviate the suppression of bone marrow activity caused by chemotherapy drugs. The objective of treating chemotherapy-induced myelosuppression is to alleviate symptoms, prevent complications such as infections or bleeding disorders, and support patients in continuing their chemotherapy treatment.
The primary indications for chemotherapy-induced myelosuppression treatment are anemia, neutropenia, and thrombocytopenia. Anemia in this context refers to a condition where the body lacks sufficient healthy red blood cells, leading to fatigue, weakness, and shortness of breath. The various classes of drugs used include growth factors, erythropoietin-stimulating agents, thrombopoietic agents, iron supplements, and others. The market for chemotherapy-induced myelosuppression treatment includes oral and injectable routes of administration, distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
The chemotherapy-induced myelosuppression treatment market research report is one of a series of new reports that provides chemotherapy-induced myelosuppression treatment market statistics, including chemotherapy-induced myelosuppression treatment industry global market size, regional shares, competitors with a chemotherapy-induced myelosuppression treatment market share, detailed chemotherapy-induced myelosuppression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy-induced myelosuppression treatment industry. This chemotherapy-induced myelosuppression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chemotherapy-induced myelosuppression treatment market includes revenues earned by entities by providing services such as red blood cell transfusions, platelet transfusions, antibiotic therapy, and supportive care and related erythropoiesis-stimulating agents, antibiotics, colony-stimulating factors (CSFs), diagnostic kits and hydration solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Chemotherapy-Induced Myelosuppression Treatment Market Characteristics3. Chemotherapy-Induced Myelosuppression Treatment Market Trends and Strategies4. Chemotherapy-Induced Myelosuppression Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Chemotherapy-Induced Myelosuppression Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Chemotherapy-Induced Myelosuppression Treatment Market34. Recent Developments in the Chemotherapy-Induced Myelosuppression Treatment Market
5. Global Chemotherapy-Induced Myelosuppression Treatment Growth Analysis and Strategic Analysis Framework
6. Chemotherapy-Induced Myelosuppression Treatment Market Segmentation
7. Chemotherapy-Induced Myelosuppression Treatment Market Regional and Country Analysis
8. Asia-Pacific Chemotherapy-Induced Myelosuppression Treatment Market
9. China Chemotherapy-Induced Myelosuppression Treatment Market
10. India Chemotherapy-Induced Myelosuppression Treatment Market
11. Japan Chemotherapy-Induced Myelosuppression Treatment Market
12. Australia Chemotherapy-Induced Myelosuppression Treatment Market
13. Indonesia Chemotherapy-Induced Myelosuppression Treatment Market
14. South Korea Chemotherapy-Induced Myelosuppression Treatment Market
15. Western Europe Chemotherapy-Induced Myelosuppression Treatment Market
16. UK Chemotherapy-Induced Myelosuppression Treatment Market
17. Germany Chemotherapy-Induced Myelosuppression Treatment Market
18. France Chemotherapy-Induced Myelosuppression Treatment Market
19. Italy Chemotherapy-Induced Myelosuppression Treatment Market
20. Spain Chemotherapy-Induced Myelosuppression Treatment Market
21. Eastern Europe Chemotherapy-Induced Myelosuppression Treatment Market
22. Russia Chemotherapy-Induced Myelosuppression Treatment Market
23. North America Chemotherapy-Induced Myelosuppression Treatment Market
24. USA Chemotherapy-Induced Myelosuppression Treatment Market
25. Canada Chemotherapy-Induced Myelosuppression Treatment Market
26. South America Chemotherapy-Induced Myelosuppression Treatment Market
27. Brazil Chemotherapy-Induced Myelosuppression Treatment Market
28. Middle East Chemotherapy-Induced Myelosuppression Treatment Market
29. Africa Chemotherapy-Induced Myelosuppression Treatment Market
30. Chemotherapy-Induced Myelosuppression Treatment Market Competitive Landscape and Company Profiles
31. Chemotherapy-Induced Myelosuppression Treatment Market Other Major and Innovative Companies
35. Chemotherapy-Induced Myelosuppression Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Chemotherapy-Induced Myelosuppression Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on chemotherapy-induced myelosuppression treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for chemotherapy-induced myelosuppression treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chemotherapy-induced myelosuppression treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Anemia; Neutropenia; Thrombocytopenia2) By Drug Class: Growth Factors; Erythropoietin Stimulating Agents; Thrombopoietic Agents; Iron Supplements; Other Drug Classes
3) By Route of Administration: Oral; Injectable
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Anemia: Erythropoiesis-Stimulating Agents (Esas); Iron Supplements; Blood Transfusion; Other Anemia Treatments2) By Neutropenia: Granulocyte Colony-Stimulating Factors (G-Csfs); Granulocyte-Macrophage Colony-Stimulating Factors (Gm-Csfs); Antibiotic Prophylaxis; Other Neutropenia Treatments
3) By Thrombocytopenia: Thrombopoietin Receptor Agonists (Tpo-Ras); Platelet Transfusion; Growth Factors for Platelet Production; Other Thrombocytopenia Treatments
Key Companies Mentioned: Merck & Co. Inc., Bayer AG, Sanofi SA, Abbott Laboratories, Novartis AG, Glaxo Smith Kline plc, Amgen Inc., Viatris Inc., Biogen SA, Bausch Health Companies Inc., Cipla Inc., Hikma Pharmaceuticals PLC,Lupin Ltd, Seagen Inc, Mission Pharmacal Company, G1 Therapeutics Inc., Spectrum Pharmaceuticals Inc., Partner Therapeutics Inc., Myelo Therapeutics GmbH, Evive Biotech Inc.;
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Chemotherapy-Induced Myelosuppression Treatment market report include:- Merck & Co. Inc., Bayer AG, Sanofi SA, Abbott Laboratories, Novartis AG, Glaxo Smith Kline plc, Amgen Inc., Viatris Inc., Biogen SA, Bausch Health Companies Inc., Cipla Inc., Hikma Pharmaceuticals PLC,Lupin Ltd, Seagen Inc, Mission Pharmacal Company, G1 Therapeutics Inc., Spectrum Pharmaceuticals Inc., Partner Therapeutics Inc., Myelo Therapeutics GmbH, Evive Biotech Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 8.37 Billion |
| Forecasted Market Value ( USD | $ 10.04 Billion |
| Compound Annual Growth Rate | 4.6% |
| Regions Covered | Global |
